Data on prognostic factors unique to
LGOs are lacking as most of the available data are derived from studies on low-grade gliomas in general, including astrocytomas and mixed tumors. 12, 25 Pure oligodendrogliomas are thought to carry a better prognosis than mixed gliomas or astrocytomas. Combined deletions on chromosomal arms 1p and 19q (1p/19 codeletion) have been linked to improved prognosis in patients with anaplastic oligodendroglioma. The prognostic and/or predictive role of this genetic alteration is not as well defined in LGO.
We have reviewed our institutional experience with adult supratentorial pure LGO, correlating outcomes with several variables of possible prognostic value, including 1p/ 19q codeletion and the methylation status at the MGMT promoter site. In this article we report our findings.
Methods
We identified cases of LGO treated between 1992 and 2006 by reviewing the pathology database of the Montreal Neurological Hospital/McGill University Health Center. In all cases the patient had undergone contrast-enhanced brain CT and/or MR imaging followed by an initial neurosurgical procedure in the form of biopsy, subtotal resection, or GTR. The extent of surgery was defined based on the surgeon's operative notes and/or postoperative images. All histopathological specimens were reviewed by a single neuropathologist (M.C.G.) who was blinded to patients' outcomes. The diagnosis of LGO was made according to the 2000 WHO classification of nervous system tumors. 13 Fluorescent in situ hybridization was used for evaluation of deletions on chromosome arms 1p and 19q, and MGMT methylation status was evaluated using methylation specific polymerase chain reaction.
After obtaining institution review board approval, all clinical, pathological, and radiological records were carefully reviewed for demographic characteristics, nature and duration of presenting symptoms, baseline neurological function, extent of resection, and KPS status. Preoperative radiological studies were inspected for tumor size, tumor location, enhancement, and presence or absence of midline shift. The timing and dose of radio-and/or chemotherapy, radiotherapy techniques, date of tumor progression, pathology at disease progression, treatment at time of disease progression, and status at the last followup were also recorded.
Outcomes were calculated from the date of surgery. Disease progression was considered to have occurred on the date of the imaging study documenting progression. Overall survival and progression-free survival time were calculated using computer-generated Kaplan-Meier curves and estimates. The following variables were analyzed for prognostic significance for overall and progression-free survival: sex, age at diagnosis (< 40 or ≥ 40 years), seizures at presentation (yes or no), duration of symptom, neurological function at presentation, KPS score, maximum tumor diameter, tumor location, contrast enhancement on imaging studies (yes or no), extent of surgery (GTR or other), postoperative radiotherapy (yes or no), chromosome arms 1p/19q codeletion (yes or no), and MGMT promoter gene methylation status. Univariate analyses were done using the log-rank test, with p < 0.05 used to indicate significance. Multivariate analysis was conducted for variables for which statistically significance was observed on univariate analysis using the Cox regression model.
Outcomes were also analyzed according to the EORTC prognostic model, 25 and the RPA for low-grade gliomas was developed by Bauman et al. 1 The EORTC prognostic scoring system for low-grade gliomas is based on a total number of adverse prognostic factors. These factors are age ≥ 40 years, tumor diameter ≥ 6 cm, tumor crossing midline, astrocytoma histology, and the presence of neurological deficits at diagnosis. In this system, patients with ≥ 3 unfavorable factors are classified as high-risk cases with an expected median overall survival of < 7 years. The RPA for low-grade gliomas developed by Bauman et al. uses KPS score, age at diagnosis, and the presence of contrast enhancement on preoperative images. Based on these variables, these authors were able to develop an RPA classification resulting in 4 different risk groups: Group I (KPS score < 70, age > 40 years), Group II (KPS score ≥ 70, age > 40 years, enhancement present), Group III (KPS score < 70, age 18-40 years; or KPS score ≥ 70, age > 40 years, no enhancement), and Group IV (KPS score ≥ 70, age 18-40 years). Group I was associated with the shortest median survival, whereas Group IV had the best outcome.
Results
Sixty-nine adult patients with supratentorial pure LGO were identified. The median follow-up period was 6.1 years (range 1.3-16.3 years). Patient characteristics are summarized in Table 1 . Seizure was the presenting symptom in the majority (78%) of patients. Preoperative radiological images were available for review in 62 patients (90%) and a radiology report only in 3 other patients. All patients underwent an initial neurosurgical procedure: GTR in 19 (27%), partial resection in 41 (59%), and biopsy only in the remaining 9 patients (13%).
Fifteen patients underwent adjuvant radiotherapy; the median interval between surgery and the start of radiation therapy was 1.7 months (range 1-7 months). For all patients, the radiation dose scheme was 54 Gy in daily fractions of 1.8 Gy.
Chemotherapy was administered to 36 patients during the course of disease. Twenty-nine received temozolomide and 7 received procarbazine, lomustine (CCNU), and vincristine; in only 5 cases was this postoperative adjuvant chemotherapy. Among patients who received chemotherapy, 22 (61%) had a methylated MGMT gene promoter, 4 (11%) had an unmethylated promoter, and the status was unavailable in the remaining 10 patients.
Data on 1p/19q status was available for all but 1 patient. Fifty-five percent of patients had a codeletion. The 1p/19q codeletion was positively associated with seizures (80%) and negatively associated with contrast enhancement (15%).
The 5-, 10-and 15-year overall survival rates were 83, 63, and 29%, respectively (Fig. 1A) , with a median survival of 12.9 years (95% CI 9.6-16.1 years). On univariate analysis, the KPS score, presence of seizures at presentation, frontal location, absence of contrast enhancement on preoperative CT and/or MR images, GTR, and 1p/19q codeletion were favorable prognostic factors for overall survival ( Table 2) . On multivariate analysis, only the presence of seizures at presentation (p = 0.01) and the lack of contrast enhancement (p = 0.002) were identified as independent favorable prognostic factors ( Table 3) .
The 5-, 10-, and 15-year progression-free survival rates were 46, 7.7, and 0%, respectively (Fig. 1B) , with a median progression-free survival of 4.9 years (95% CI 3.7-6 years). The median time to progression was higher after GTR (5.7 compared with 4.7 years), but this difference did not reach significance (p = 0.16). Similarly, there was no significant difference in 5-or 10-year progression-free survival rates for grossly resected and incompletely resected tumors: 55 versus 42% and 8 versus 0%, respectively. On univariate analysis, the absence of contrast enhancement on pretreatment images and 1p/19q codeletion were the only variables that reached statistical significance (both p = 0.01, log-rank test). Statistical significance was maintained on multivariate analysis for enhancement (HR 2. During the follow-up period, 47 patients (68%) developed imaging-confirmed disease progression. At progression, 9 patients had malignant transformation (anaplastic oligodendroglioma in 7, anaplastic oligoastrocytoma in 1, and glioblastoma multiforme in 1). The median time to malignant transformation was 4.7 years. Resection was the primary treatment in 37 patients at progression. Of these, 13 patients underwent postoperative chemotherapy. Radiation therapy was administered in 7 patients after salvage surgery: alone in 3 cases (54-Gy dose in 30 fractions) and with concurrent temozolomide in the other 4 patients (total dose range 59.4-60 Gy).
When applying the EORTC scoring system in our cases, only 7 patients had 3 unfavorable prognostic factors. The median survival in these 7 high-risk patients was 6.5 years, in contrast to 12.8 years in the remaining patients classified as low risk (p = 0.1). In applying the Bauman RPA classification, 1 4 patients met the criteria for Group I, 8 for Group II, 22 for Group III, and 35 for Group IV. For the outcome analysis, given the relatively small number of patients in each group, we combined Groups I and II and Groups III and IV. The median overall survival in Groups I/II was 5.5 years, whereas that in Groups III/IV was 13.8 years (p = 0.004, HR 0.15 [95% CI 0.04-0.5]). This is illustrated in Fig. 1C . 
Discussion
We have reported on our long-term experience with LGO. Our results in terms of median survival and as actuarial 5-and 10-year overall survival rates are comparable with those cited in prior reports. The authors of contemporary series have reported median survival times for LGO of 10-12.1 years 18,22,23 with 5-and 10-year survival rates of 68-88% 16, 19, 22, 41 and 51-85%, 16, 22 respectively. Our median time to progression and 5-year progression-free survival rate are also comparable to other published series.
16,23
In older series, authors used different histological clas sifications, which makes comparison of outcomes among series difficult. In a series of 68 patients with oligodendroglioma, including 14 patients with malignant oligodendrogliomas and 6 with oligoastrocytomas treated between 1958 and 1984, Nijjar et al. 21 reported 5-and 10-year survival rates of 66 and 30%, respectively, for the whole group, and the median time to progression was 2.6 years. In the Mayo clinic experience, with the use of the St. Anne-Mayo classification system, 4 the median survival for Grade I/II disease was 9.7 years with a 10-year overall survival rate of 43%. 30 In our series, 13% of the patients had only a biopsy, and the possibility that an astrocytic component was present in the remaining tumor cannot be completely ruled out.
Available data present conflicting conclusions on the prognostic importance of various clinical and pathological factors. 19 Any analysis of prognostic factors is complicated by the relative rarity of this disease and the fact that many prognostic factors are interrelated. Despite the analysis of promising molecular studies, we have identified only 2 independent prognostic factors for overall survival: initial contrast enhancement on imaging and seizures at presentation.
Seizures have been previously identified as a favorable prognostic factor for patients with LGO 16 and lowgrade gliomas in general. 17 In the EORTC experience, the presence of seizures was significant only on univariate analysis with the authors suggesting that the influence of seizures on outcomes may be related to its negative association with neurological deficits and poor performance status, thus losing its significance when these factors are taken into account. 25 In the present series, seizures were not associated with worse neurological function or poor KPS score but did seem to be correlated with the more favorable 1p/19q-codeleted tumors.
Contrast enhancement is more frequently associated with high-grade disease, and its presence in low-grade tumors has been thought to be due to undersampled foci of anaplasia. 27 In 2 studies, the pattern of CT and MR imaging contrast enhancement in WHO Grade II and III oligodendrogliomas was correlated with histopathological grade. The rate of contrast enhancement was similar in both groups: 50-56% in WHO Grade II oligodendrogliomas and 50-62% of Grade III tumors, with no significant difference regarding the degree of enhancement.
26,40
It was concluded that enhancement was not a surrogate for grade. A large prospective study on low-grade gliomas (> 68% of the patients had LGOs or predominantly oligodendroglial mixed tumors) showed no statistically significant prognostic role for contrast enhancement. 28 On the other hand, multiple retrospective studies have suggested that contrast enhancement confers a worse prognosis in LGOs. 15, 16, 30, 37 In the EORTC prognostic model for low-grade gliomas, age has been identified as an independent prognostic factor. 25 In LGO retrospective series, authors have come to different conclusions, either supporting the significance of age 15, 16, 21, 41 or, as is our case, failing to show a significant independent effect of a patient's age on survival. 18, 19, 21, 22, 36 Despite this, and likely because of the strong effect of contrast enhancement, the prognostic significance of the Bauman RPA, which relies heavily on age, held up in our series.
Other prognostic factors highlighted in prior reviews, 17, 25, 27 such as duration of symptoms prior to diagnosis, performance status, and neurological function at presentation, were not prognostic in our series, although we may be hobbled by the small size of some subgroups.
The impact of the extent of initial resection in lowgrade gliomas has been a subject of major controversy. All available data come from retrospective or post hoc analysis. Moreover, prior studies focusing on oligodendrogliomas included a mix of low-and high-grade tumors.
11, 35 Smith et al. 31 reported in a group of 216 patients (42% with LGO) that extent of resection was a statistically significant predictor of overall survival. Another retrospective study suggested only improved progression-free survival after complete resection.
2 Other reviews, in accordance with our own series, have failed to demonstrate any impact of the extent of surgery in LGO. 15, 16, 19, 36, 41 In a postsurgical observational trial for patients with favorable low-grade gliomas, data from the RTOG (Radiation Therapy Oncology Group) 9802 trial showed poor 5-year progression-free survival rate (50%) even after GTR.
29
Because no prospective study is planned, resected and resectable tumors will continue to be confused.
We have randomized data supporting that postoperative radiotherapy clearly increases progression-free survival in patients with low-grade gliomas. 10, 33 However, delaying progression did not appear to translate into improved survival, and the morbidity associated with treatment must be weighed against the morbidity attendant on early progression on a case-by-case basis. A recent retrospective study limited to 52 patients with LGO suggested that there was a statistically significant effect (p = 0.0002) on overall survival associated with postoperative radiotherapy. 41 In that study, 23 patients received postoperative radiotherapy to a minimum dose of 56 Gy (range 56-70 Gy) in 2-Gy fractions. Based on our results we found no prognostic significance of postoperative radiotherapy on either progression-free or overall survival, results in agreement with other reviews of LGO.
21,23,24
Combined deletion of chromosome arms 1p and 19q has been observed in up to 70% of oligodendrogliomas.
9 It has been noted that its presence in patients with oligodendroglioma is usually associated with low-grade tumors that usually present with seizures and tend to remain stable for a prolonged period. 34 A 1p/19q codeletion has been associated with improved overall and progression-free survival in patients with anaplastic oligodendrogliomas, 3 but its role as a prognostic marker is not well defined in low-grade tumors. All the studies included inhomogeneous patient populations with either other low-grade gliomas or anaplastic oligodendrogliomas. While several studies suggested that a 1p/19q codeletion has a significant prognostic effect on progression-free survival, 7, 8, 14, 32, 38 others reported no such prognostic significance. 22, 39 In the current study, 55% of patients had a 1p/19q codeletion. The median survival time in patients with a 1p/19q codeletion was 13.8 years compared with 9 years in patients without this codeletion. Most patients (81%) with a 1p/19q codeletion presented with seizures and a minority (26%) had contrast enhancement on initial imaging. These associations likely explained why, on multivariate analysis, there was no statistically significant effect of codeletion on survival.
34
The MGMT promoter gene hypermethylation has been linked to an improved response of malignant gliomas to alkylating agents via deactivation of the MGMT protein responsible of repair of DNA damage produced by alkylating agents. 27 Studies have shown that MGMT methylation is more frequent in oligodendrogliomas with 1p/19q codeletion. 5, 20 In our results MGMT promoter gene methylation was strongly associated with 1p/19q codeletion-67% of methylated tumors had 1p/19q codeletion and vice versa. Unfortunately, MGMT methylation status was not known in one-third of our patients. Moreover, only 4 patients having received chemotherapy had a known methylation status. Accordingly we were not able to assess the effect of MGMT on response to chemotherapy. Independent of treatment, promoter methylation had no significant effect on overall or progression-free survival.
Conclusions
Our long-term data illustrate the indolent but progressively fatal course of pure LGO. Despite the fact that onethird of our patients underwent initial GTR, all tumors were expected to progress by 15 years. In accordance with trials for low-grade gliomas in general, our data failed to show an impact of the initial treatment strategy on overall survival. Our analysis of prognostic factors highlighted initial contrast enhancement as the most significant independent prognostic factor for survival. Contrast enhancement was inversely associated with seizures at presentation and 1p/19q codeletion-2 favorable prognostic factors. Recursive partitioning analysis groupings for low-grade gliomas were prognostic when applied to a population of pure LGOs. Despite the favorable prognosis of some subgroups of LGO, new treatment strategies will be needed to offer patients hope for a definitive cure.
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